-
Arsenal crowned Premier League champions after Man City draw
-
New York art auctions roar back with blockbuster sales
-
US says held talks with Cuba on $100 mln offer
-
Chelsea beat Spurs to leave rivals in 'embarrassing' relegation danger
-
Google wants its search bar to act on your behalf in AI revamp
-
Taiwan author wins International Booker for 'slyly sophisticated' novel
-
Iran 'very confident' about World Cup protocols: federation vice-president
-
Google unveils smart glasses, taking on Meta
-
Guardiola swerves Man City exit talk as title hopes ended
-
Chiefs' Rice jailed for probation violation
-
Five factors in Arsenal's Premier League title triumph
-
Mikel Arteta: Pep protege to Premier League winner
-
How Arsenal banished 'nearly men' tag to end 22-year title wait
-
Arsenal win Premier League after Man City held by Bournemouth
-
From graduation boos to voter unease: AI anxiety grows in the US
-
Lost in Trump's climate boast: best-case scenario abandoned
-
Hantavirus cruise operator says ship not source of outbreak
-
Trump shows off ballroom site with 'drone empire' planned for roof
-
Rubio to attend NATO talks, pay first visit to India
-
Under Trump pressure, EU seeks deal to end trade standoff
-
Airbus seeks to cut peripheral expenses due to Mideast war
-
France encourages women to report rape in probes of star Bruel
-
Guardiola silent on Man City exit reports
-
Argentine researchers collect rodents for hantavirus tests
-
Iran talks making 'good progress': US VP Vance
-
Teen wonder Sooryavanshi's slams 93 to edge Rajasthan closer to IPL play-offs
-
Norway reports Europe's first case of bird flu in a polar bear
-
Italy's Ganna wins time-trial in Giro shake-up
-
EU vows help for farmers hit by Iran war fertiliser price hikes
-
Emery focused on Villa glory, not crown of Europa League 'king'
-
French govt slams 'disproportionate' Canal+ riposte to anti-Bollore petition
-
US, Iran trade threats but Trump says Tehran wants peace deal
-
Russia's Zvyagintsev sets film amid 'disaster' Ukraine war
-
UK trade minister hopes Britain will rejoin EU 'in my lifetime'
-
Race to find vaccines, treatments for Ebola strain behind outbreak
-
King Charles III bangs drum for Irish music, eyes hip-hop lesson
-
Ganna wins time-trial in Giro shake-up
-
Drone attack kills 28 at market in southern Sudan
-
Putin lands in China for trip that aims to show unshakeable ties after Trump pomp
-
Israel finance minister says ICC seeks arrest warrant against him
-
Kentucky primary vote tests Trump's grip on Republican base
-
Alcaraz withdraws from Wimbledon with wrist injury
-
Indie game plunges players into sci-fi epic 'Battlestar Galactica'
-
Trump shows off site of new $400-mn ballroom
-
Israeli troops in Iraq: what do we know?
-
Iran warns against new US attacks as Trump says held off assault
-
Oil dips, stocks mixed after Trump holds off on Iran attack
-
India rest Bumrah for one-off Test against Afghanistan
-
G7 finance ministers vow cooperation to face 'heightened risks'
-
Ghana, Ivory Coast to clash in 2027 AFCON qualifying
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection
Delivering Effective Germ Control in Five Minutes
BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.*
NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential.
"We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patient safety and manage infections more effectively."
The European Centre for Disease Prevention and Control reports that these infections result in over 3.5 million cases each year in the EU and EEA, causing more than 90,000 deaths. Effective infection control practices could prevent up to 50% of healthcare-associated infections (HAIs).* NUGEN® HLD-CD delivers powerful protection - arming frontline healthcare teams with a fast, effective tool to stop infections before they spread.
Additionally, NUGEN® HLD-CD is an ideal solution for targeting Clostridium difficile (C. diff) contamination*, a common and challenging pathogen in healthcare settings that spreads via contact with contaminated surfaces.
For more information about NUGEN® HLD-CD and its applications, please visit https://www.arxada.com/en/hygiene/hygiene-emea/nugen-hld-cd or contact [email protected]
Media contacts:
Tricia Ryan
External Corporate Communications
Arxada
[email protected]
Jane Smith
Marketing Communications, Professional Hygiene
Arxada
[email protected]
About Arxada
Arxada is a global science-based specialty chemicals business creating innovative chemistry and solutions. With customers in more than 100 countries, it achieved sales of CHF 2.0 billion in 2023. The company aims to solve the world's toughest preservation challenges by enhancing sustainability with cleaner, greener solutions. Arxada focuses on multiple end-markets, primarily in: Human Health & Nutrition, Home & Personal Care, Paints & Coatings and Wood Protection, providing a broad portfolio of differentiated products and solutions, supported by its and innovation capabilities, in-depth regulatory know-how and track record in manufacturing and process development. Headquartered in Basel (Switzerland), the company's 3,400 employees contribute to the success of its customers, spanning 24 production sites and 14 R&D centers. To learn more about Arxada, please visit: www.arxada.com and Arxada on LinkedIn.
This product is intended for use as a medical device within the European Union and is sold exclusively to healthcare professionals. It has undergone a conformity assessment to ensure compliance with EU regulations, including the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. The product is designed to meet the highest standards of safety and performance. Users are advised to follow the instructions for use provided by the manufacturer. The manufacturer is not liable for any misuse or off-label use of the product. All trademarks belong to Arxada or its affiliates. © 2025 Arxada.
*Data on file with Arxada; based on internal and external testing
SOURCE: Enviro Tech Chemical Services, Inc.
View the original press release on ACCESS Newswire
X.AbuJaber--SF-PST